[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

RU2006110036A - Лечение глазных расстройств анти-cd20 - Google Patents

Лечение глазных расстройств анти-cd20 Download PDF

Info

Publication number
RU2006110036A
RU2006110036A RU2006110036/13A RU2006110036A RU2006110036A RU 2006110036 A RU2006110036 A RU 2006110036A RU 2006110036/13 A RU2006110036/13 A RU 2006110036/13A RU 2006110036 A RU2006110036 A RU 2006110036A RU 2006110036 A RU2006110036 A RU 2006110036A
Authority
RU
Russia
Prior art keywords
antibody
eye
mammal
fragment
antagonist
Prior art date
Application number
RU2006110036/13A
Other languages
English (en)
Inventor
Пол Дж. БРУНЕТТА (US)
Пол Дж. БРУНЕТТА
Original Assignee
Дженентек, Инк. (Us)
Дженентек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дженентек, Инк. (Us), Дженентек, Инк. filed Critical Дженентек, Инк. (Us)
Publication of RU2006110036A publication Critical patent/RU2006110036A/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (17)

1. Способ лечения глазного расстройства у млекопитающего, предусматривающий введение антагониста CD20 млекопитающему в количестве, эффективном для лечения глазного расстройства.
2. Способ по п.1, где антагонист состоит из антитела.
3. Способ по п.1, где млекопитающее является человеком.
4. Способ по п.2, где антитело не конъюгировано с цитотоксическим средством.
5. Способ по п.2, где антитело состоит из ритуксимаба.
6. Способ по п.2, где антитело состоит из гуманизированного 2H7.
7. Способ по п.2, где антитело конъюгировано с цитотоксическим средством.
8. Способ по п.1, который, по существу, состоит из введения антагониста млекопитающему.
9. Способ по п.1, где млекопитающее производит аутоантитела, которые связываются с более чем одним глазным антигеном, или имеет иммунные комплексы в глазу.
10. Способ по п.1, где глазное расстройство выбрано из группы, состоящей из увеита, ирита, тиреоидной болезни глаз или офтальмологии Грейвса, поражения глаз при болезни Бехчета, myasthenia gravis глаз, пемфигоида глаз, аутоиммунной ретинопатии, онхоцеркоза, эписклерита, склерита, рецидивирующего неврита зрительного нерва, зависимого от стероидов, поражения глаз при гранулематозе Вегенера, глазного осложнения Шегрена, ретинопатии, вызванной меланомой, и ретинопатии, вызванной раком.
11. Способ по п.1, где антитело является интактным антителом.
12. Способ по п.1, где антитело является фрагментом антитела, который содержит антигенсвязывающую область, которая связывает CD20.
13. Способ по п.12, где фрагмент антитела выбран из группы, состоящей из Fab, Fab', F(ab')2, Fv, одноцепочечного Fv-фрагмента (scFv) и диатела.
14. Способ по п.1, где антитело вводится внутривенно.
15. Способ по п.1, где антитело вводится посредством внутриглазничной, внутрикамерной, окологлазничной инъекции или инъекции в стекловидное тело.
16. Способ по п.15, где антитело является фрагментом антитела, который содержит антигенсвязывающую область, которая связывает CD20.
17. Способ по п.1, где антитело вводится в глаз местно.
RU2006110036/13A 2003-08-29 2004-08-20 Лечение глазных расстройств анти-cd20 RU2006110036A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49879103P 2003-08-29 2003-08-29
US60/498,791 2003-08-29

Publications (1)

Publication Number Publication Date
RU2006110036A true RU2006110036A (ru) 2006-08-10

Family

ID=34272728

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006110036/13A RU2006110036A (ru) 2003-08-29 2004-08-20 Лечение глазных расстройств анти-cd20

Country Status (14)

Country Link
US (2) US20050053602A1 (ru)
EP (1) EP1660129A2 (ru)
JP (1) JP2007504138A (ru)
KR (1) KR20060132554A (ru)
CN (1) CN1845755A (ru)
AU (1) AU2004270165A1 (ru)
BR (1) BRPI0412629A (ru)
CA (1) CA2535895A1 (ru)
IL (1) IL173351A0 (ru)
MX (1) MXPA06002134A (ru)
NO (1) NO20061412L (ru)
RU (1) RU2006110036A (ru)
WO (1) WO2005023302A2 (ru)
ZA (1) ZA200601218B (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020027311A (ko) 1999-05-07 2002-04-13 제넨테크, 인크. B 세포 표면 마커에 결합하는 길항물질을 이용한자가면역 질환의 치료
CA2422076A1 (en) * 2000-09-18 2002-03-21 Idec Pharmaceutical Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
JP5416338B2 (ja) * 2003-05-09 2014-02-12 デューク ユニバーシティ Cd20特異的抗体およびその使用方法
BR122020013239B1 (pt) * 2003-11-05 2022-05-10 Roche Glycart Ag Anticorpo anti-cd20 humano tipo ii humanizado, seus usos, bem como composição farmacêutica
US20060051345A1 (en) 2004-06-04 2006-03-09 Genentech, Inc. Method for treating multiple sclerosis
SV2006002131A (es) * 2004-06-04 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento de lupus
EP1781378A2 (en) * 2004-07-22 2007-05-09 Genentech, Inc. Method of treating sjögren's syndrome
CN101087807A (zh) * 2004-10-05 2007-12-12 健泰科生物技术公司 治疗血管炎的方法
AR053579A1 (es) * 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
ES2341484T3 (es) * 2005-05-20 2010-06-21 Genentech, Inc. Pretratamiento de una muestra biologica de un sujeto que sufre una enfermedad autoinmune.
AU2008282152B2 (en) 2007-07-31 2013-12-19 Regeneron Pharmaceuticals, Inc. Human antibodies to human CD20 and method of using thereof
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
WO2016081490A1 (en) 2014-11-17 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods for tumor treatment using cd3xcd20 bispecific antibody
US11590223B2 (en) 2018-08-31 2023-02-28 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for therapeutic antibodies

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5506126A (en) * 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
US4861579A (en) * 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
US7744877B2 (en) * 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
ATE196606T1 (de) * 1992-11-13 2000-10-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AU8296098A (en) * 1997-07-08 1999-02-08 Board Of Regents, The University Of Texas System Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6242195B1 (en) * 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
PL195870B1 (pl) * 1998-08-11 2007-11-30 Biogen Idec Inc Zastosowanie przeciwciała anty-CD20, zastosowanieznakowanego radioaktywnie przeciwciała anty-CD20,zastosowanie przeciwciała anty-CD20 do przygotowania leku zwierającego przeciwciało i chemioterapięoraz zastosowanie przeciwciała anty-CD20 do przygotowania leku zawierającego przeciwciało i szpik kostny
US6224866B1 (en) * 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
EP1035172A3 (en) * 1999-03-12 2002-11-27 Fuji Photo Film Co., Ltd. Azomethine compound and oily magenta ink
DK1194167T3 (da) * 1999-06-09 2009-11-16 Immunomedics Inc Immunoterapi af autoimmune sygdomme under anvendelse af B-cellespecifikke antistoffer
DE19930748C2 (de) * 1999-07-02 2001-05-17 Infineon Technologies Ag Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip
NZ516491A (en) * 1999-07-12 2004-11-26 Idec Pharmaceuticals Inc Blocking immune response to a foreign antigen using an antagonist which binds to CD20
US20020006404A1 (en) * 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
JP2004500412A (ja) * 2000-03-31 2004-01-08 アイデック ファーマスーティカルズ コーポレイション B細胞リンパ腫の治療のための抗サイトカイン抗体またはアンタゴニストおよび抗cd20の併用
NZ521540A (en) * 2000-04-11 2004-09-24 Genentech Inc Multivalent antibodies and uses therefor
AU2001259142C1 (en) * 2000-04-25 2006-11-23 Biogen Idec Inc. Intrathecal administration of rituximab for treatment of central nervous system lymphomas
DK1296714T3 (da) * 2000-06-22 2009-12-07 Coley Pharm Gmbh Kombination af CpG og antistoffer, der er rettet mod CD19, CD20, CD22 eller CD40 til behandling eller forebyggelse af kræft
CA2422076A1 (en) * 2000-09-18 2002-03-21 Idec Pharmaceutical Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
AU2002250352C1 (en) * 2001-04-02 2009-04-30 Genentech, Inc. Combination therapy
IL158316A0 (en) * 2001-04-10 2004-05-12 Univ Leland Stanford Junior Therapeutic and diagnostic uses of antibody specificity profiles
AU2002327037A1 (en) * 2001-09-20 2003-04-01 Board Of Regents, The University Of Texas System Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays
US20030157108A1 (en) * 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US20030147865A1 (en) * 2002-02-07 2003-08-07 Benoit Salomon Cell therapy using immunoregulatory T-cells
KR20090088973A (ko) * 2002-10-17 2009-08-20 젠맵 에이/에스 Cd20에 대한 인간 모노클로날 항체
KR20110044809A (ko) * 2003-04-09 2011-04-29 제넨테크, 인크. Tnf-알파 저해제에 대해 부적절한 반응을 하는 환자에서의 자가면역 질환의 치료법

Also Published As

Publication number Publication date
WO2005023302A3 (en) 2005-04-28
ZA200601218B (en) 2007-05-30
BRPI0412629A (pt) 2006-09-26
EP1660129A2 (en) 2006-05-31
AU2004270165A1 (en) 2005-03-17
NO20061412L (no) 2006-03-28
US20050053602A1 (en) 2005-03-10
IL173351A0 (en) 2006-06-11
CA2535895A1 (en) 2005-03-17
US20090136492A1 (en) 2009-05-28
WO2005023302A2 (en) 2005-03-17
MXPA06002134A (es) 2006-05-31
JP2007504138A (ja) 2007-03-01
KR20060132554A (ko) 2006-12-21
CN1845755A (zh) 2006-10-11

Similar Documents

Publication Publication Date Title
RU2006110036A (ru) Лечение глазных расстройств анти-cd20
US8633301B2 (en) Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
CN106334187B (zh) 包含特异性识别cd38的抗体和硼替佐米的抗肿瘤组合
AU2009321252B2 (en) Antitumor combinations containing antibodies recognizing specifically CD38 and cylophosphamide
US9259406B2 (en) Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
RU2019116624A (ru) Новые анти_cd137 антитела и их применение
KR20220025946A (ko) 항-egfr 항체 및 항체 약물 접합체
JP2010528047A5 (ru)
JP2010520290A5 (ru)
CN110799535A (zh) 抗folr1免疫缀合物与抗pd-1抗体的组合
CA3225908A1 (en) Treatment of anti-pla2r autoantibody-mediated membranous nephropathy
AU2007299582B2 (en) Anti-cancer antibodies against Lewisy and Lewisb antigens
KR20190110063A (ko) 항-vegfr-2 항체
IL314344A (en) Bispecific antibodies against CD3 and CD20 in combination therapy for the treatment of diffuse large B-cell lymphoma
WO2024112561A1 (en) Methods for the treatment of myasthenia gravis
AU2005211669C1 (en) Treatment of intermediate- and high-grade non-Hodgkins lymphoma with anti-CD20 antibody
RU2004137274A (ru) Антитела против миелин-ассоциированного гликопротеина (mag)
IL311796A (en) Anti-galectin-9 antibodies and their therapeutic uses
RU2021133162A (ru) Способы лечения рака предстательной железы с помощью антитела к psma/cd3
JPWO2021092380A5 (ru)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20100112